Brief: Hutchmed China Ltd says Savannah Phase II trial shows high response rates with Savolitinib plus Tagrisso
20/03/2025 07:42
March 20 (Reuters) - HUTCHMED (China) Ltd 0013.HK: HUTCHMED CHINA LTD - HUTCHMED HIGHLIGHTS SAVOLITINIB SAVANNAH PHASE II HUTCHMED (CHINA) LTD - SAVANNAH PHASE II TRIAL SHOWS HIGH RESPONSE RATES WITH SAVOLITINIB PLUS TAGRISSO Source text: ID:nRST3633Ba Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))